Aptose's AML Drug Shows 86% Remission, 100% in TP53-Mutated Patients in Phase 1/2 Trial
Summary
Aptose Biosciences reported strong Phase 1/2 clinical data for its tuspetinib triplet therapy in newly diagnosed AML, achieving an 86.2% overall complete remission rate and 100% CR in patients with difficult-to-treat *TP53* mutations at the highest dose. The therapy also showed a favorable safety profile. This positive update on a key pipeline asset provides a significant de-risking event for the company. It comes amidst a delayed acquisition by Hanmi Pharmaceutical and recent disclosures of insufficient cash to fund operations, potentially influencing the acquisition's outcome or strengthening the company's standalone value if the deal collapses.
At the time of this announcement, APTOF was trading at $1.61 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.64 to $2.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.